Issue Date: March 20, 2017
Allergan, Editas form eye drug alliance
Allergan and Editas Medicine have established an ophthalmic-disease-related R&D alliance. Allergan will pay $90 million up front to access up to five early-stage CRISPR genome-editing programs at Editas. Included is Editas’s lead program for Leber congenital amaurosis, a rare, inherited retinal degenerative disease. Allergan will be responsible for developing and commercializing any resulting products. Editas could codevelop up to two.
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society